• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Tharimmune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8/26/25 5:24:20 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THAR alert in real time by email
    true 0001861657 0001861657 2025-08-26 2025-08-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K/A

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) August 26, 2025

     

    THARIMMUNE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41210   84-2642541
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I. R. S. Employer
    Identification No.)

     

    34 Shrewsbury Avenue, Suite 1C

    Red Bank, NJ 07701

    (Address of principal executive offices, including zip code)

     

    (732) 889-3111

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, $0.0001 par value   THAR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    Tharimmune, Inc. (the “Company”) is filing this Current Report on Form 8-K/A (this “Amended Report”) to include Exhibits 10.1, 10.2 and 4.1.

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On August 26, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) in relation to a registered direct offering (the “Offering”) with certain purchasers, under the Shelf Registration Statement (as defined below), of $5.35 million of the Company’s securities (the “Securities”), consisting of 1,188,888 shares of Common Stock, par value $0.0001 per share (or common stock equivalents) at a price of $4.50 per share of Common Stock.

     

    In relation to the Offering, a shelf registration statement on Form S-3 (File No. 333-270684, the “Shelf Registration Statement”) relating to the securities being offered in the Offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on March 24, 2023. The shares of Common Stock and shares underlying the Pre-Funded Warrants are being offered only by means of a prospectus supplement and the accompanying prospectus filed with the SEC.

     

    The Offering is expected to close on August 27, 2025 subject to customary closing conditions.

     

    Pursuant to a placement agency agreement dated as of August 26, 2025 (the “Placement Agency Agreement”), the Company engaged President Street Global, LLC and RF Lafferty & Co., Inc. (collectively, the “Placement Agents”) to act as the exclusive co-placement agents in connection with the Offering. The Company has agreed to pay the Placement Agents a cash fee equal to 10.0% of the aggregate gross proceeds from the sale of the securities.

     

    The foregoing descriptions of the Purchase Agreement, Placement Agency Agreement and the Form of Pre-Funded Warrant are qualified in their entirety by reference to the full text of the forms thereof, which are attached as Exhibits 10.1, 10.2 and 4.1, respectively, hereto and incorporated by reference herein.

     

    A copy of the opinion of Sheppard Mullin Richter & Hampton LLP relating to the validity of the Securities is filed herewith as Exhibit 5.1.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.  Description
    4.1  Form of Pre-Funded Warrant
    5.1  Opinion of Sheppard Mullin Richter & Hampton LLP
    10.1  Form of Securities Purchase Agreement
    10.2  Placement Agency Agreement
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 26, 2025 Tharimmune, Inc.
       
      /s/ Sireesh Appajosyula
      Sireesh Appajosyula
      Chief Executive Officer

     

     

     

    Get the next $THAR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THAR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rickel Nancy Davis

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    8/29/25 4:30:18 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kahler Thomas Clay

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    8/22/25 4:20:05 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liddy James Gordon

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    8/22/25 4:15:28 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

    BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Dr

    12/16/24 8:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

    BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 pe

    12/6/24 4:15:00 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

    Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, ope

    11/18/24 8:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    SEC Filings

    View All

    SEC Form 424B5 filed by Tharimmune Inc.

    424B5 - Tharimmune, Inc. (0001861657) (Filer)

    8/27/25 10:48:57 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tharimmune Inc.

    S-3 - Tharimmune, Inc. (0001861657) (Filer)

    8/26/25 5:25:52 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Tharimmune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K/A - Tharimmune, Inc. (0001861657) (Filer)

    8/26/25 5:24:20 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

    BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Dr

    12/16/24 8:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

    BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified the

    7/22/24 8:30:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

    BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team."Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his wide-ranging accomplishments and business insight will meaningfully strengthen our organization. In particular, we expect that his understanding of publicly traded company operations coupled with his leadership skills will provide stra

    7/17/24 8:30:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Financials

    Live finance-specific insights

    View All

    Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

    BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 /Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.Under the terms of the agreement, Tharimmune licensed global development and commercia

    9/16/24 7:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care